Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc. and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-453-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.15 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
How were Infinity Pharmaceuticals' earnings last quarter?
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) posted its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.03. The biotechnology company had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.05 million. View Infinity Pharmaceuticals' Earnings History.
When is Infinity Pharmaceuticals' next earnings date?
What price target have analysts set for INFI?
5 equities research analysts have issued 1-year price targets for Infinity Pharmaceuticals' shares. Their predictions range from $3.00 to $4.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $3.50 in the next year. This suggests a possible upside of 103.5% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals.
What is the consensus analysts' recommendation for Infinity Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 sell ratings, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Infinity Pharmaceuticals.
Has Infinity Pharmaceuticals been receiving favorable news coverage?
Media stories about INFI stock have been trending somewhat positive on Friday, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Infinity Pharmaceuticals earned a news impact score of 1.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are some of Infinity Pharmaceuticals' key competitors?
Some companies that are related to Infinity Pharmaceuticals include OptiNose (OPTN), Progenics Pharmaceuticals (PGNX), Aptorum Group (APM), Abeona Therapeutics (ABEO), BioDelivery Sciences International (BDSI), Sinovac Biotech (SVA), Albireo Pharma (ALBO), ImmunoGen (IMGN), Kadmon (KDMN), MediciNova (MNOV), Insys Therapeutics (INSY), Kezar Life Sciences (KZR), Keryx Biopharmaceuticals (KERX), Kindred Biosciences (KIN) and Urovant Sciences (UROV).
What other stocks do shareholders of Infinity Pharmaceuticals own?
Who are Infinity Pharmaceuticals' key executives?
Infinity Pharmaceuticals' management team includes the folowing people:
- Ms. Adelene Q. Perkins, Chairman & CEO (Age 59)
- Dr. Lawrence E. Bloch, Pres & Treasurer (Age 53)
- Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 52)
- Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 40)
- Ms. Melissa Hackel, VP of Fin.
Who are Infinity Pharmaceuticals' major shareholders?
Infinity Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (1.94%), Dimensional Fund Advisors LP (1.94%), Acadian Asset Management LLC (0.85%), Fosun International Ltd (0.67%), Two Sigma Investments LP (0.16%) and Clear Harbor Asset Management LLC (0.13%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok, Lawrence E Bloch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.
Which institutional investors are selling Infinity Pharmaceuticals stock?
INFI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Clear Harbor Asset Management LLC and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Infinity Pharmaceuticals company stock in the last year include Adelene Q Perkins and Jeffery Kutok. View Insider Buying and Selling for Infinity Pharmaceuticals.
Which institutional investors are buying Infinity Pharmaceuticals stock?
INFI stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Alambic Investment Management L.P., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Two Sigma Securities LLC, Bank of New York Mellon Corp, Virtu Financial LLC and Two Sigma Investments LP. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.
How do I buy shares of Infinity Pharmaceuticals?
Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Infinity Pharmaceuticals' stock price today?
One share of INFI stock can currently be purchased for approximately $1.72.
How big of a company is Infinity Pharmaceuticals?
Infinity Pharmaceuticals has a market capitalization of $97.92 million and generates $22.15 million in revenue each year. The biotechnology company earns $-11,250,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.
What is Infinity Pharmaceuticals' official website?
How can I contact Infinity Pharmaceuticals?
Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]
MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
